For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Bio-Technology General Corporation

USPTO Granted Patents = 67

EPO Patents = 2

Forward Citations = 953

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Avigdor Levanon (26 out of 28 patents)

Amos B Oppenheim (20 out of 23 patents)

Marian Gorecki (19 out of 21 patents)

4. Jacob R Hartman (15 out of 32 patents)

5. Tikva Vogel (14 out of 15 patents)

6. Moshe M Werber (12 out of 13 patents)

7. Haim Aviv (10 out of 16 patents)

8. Elisha P Zeelon (10 out of 10 patents)

9. Meir Fischer (8 out of 8 patents)

10. Rachel Guy (7 out of 9 patents)

11. Amos Panet (7 out of 8 patents)

12. Yaffa Beck (6 out of 6 patents)

13. Menachem Zeevi (5 out of 5 patents)

14. Benjamin Greenman (5 out of 5 patents)

15. Hilla Locker-Giladi (4 out of 4 patents)

Core Competencies:

Superoxide Dismutase

Polypeptide

Gene Encoding

Factor Xa Inhibitor

Recombinant Proteins

Expression Vectors

Therapeutic Compositions

Human Growth Hormone

Cloning Methods

Fibrin Binding Domain

Oxandrolone Treatment

Hyaluronic Acid

67 patents: Sort by Forward Citations

1. 6670351 - Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 (2003-12-30),

2. 6610520 - Gene encoding human manganese superoxide dismutase and recombinant polypeptide encoded thereby (2003-08-26),

3. 6576659 - Use of oxandrolone in the treatment of burns an other wounds (2003-06-10),

4. 6361772 - Human manganese superoxide dismutase DNA, its expression and method of recovering human manganese superoxide dismutase (2002-03-26),

5. 6211341 - Polypeptide having factor Xa inhibitory activity (2001-04-03),

6. 6121426 - Fibrin binding domain polypeptides and uses and methods of producing same (2000-09-19),

7. 6054291 - Expression vectors for enhanced production of polypeptides, plasmids (2000-04-25),

8. 6030611 - Therapeutic SOD compositions and uses thereof (2000-02-29),

9. 6010875 - Expressions plasmids containing the deo promoter, and bacterial hosts (2000-01-04),

10. 6008193 - Methods of using human von Willebrand factor GPIb binding domain (1999-12-28),

11. 6001604 - Refolding of proinsulins without addition of reducing agents (1999-12-14),

12. 5965383 - Fibrin binding domain polypeptides and uses and methods of producing same (1999-10-12),

13. 5948668 - Production of enzymatically active recombinant carboxypeptidase B (1999-09-07),

14. 5945304 - Expression plasmids regulated by an osmB promoter (1999-08-31),

15. 5872147 - Use of oxandrolone in the treatment of chronic obstructive pulmonary (1999-02-16),

Company Overview

Bio-Technology General Corporation, based in New York, specializes in the development and manufacturing of innovative biopharmaceuticals. The company focuses on advanced therapeutic compositions, particularly in the realm of superoxide dismutase and recombinant proteins. Its research encompasses critical areas such as gene encoding, polypeptide synthesis, and the development of expression vectors. With a commitment to enhancing human health, Bio-Technology General Corporation is at the forefront of creating effective treatments, including Factor Xa inhibitors and human growth hormone therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

67 Patents

#151 in New York, NY

#325 in New York

#5,461 in US

#11,040 in the World

New York, NY, United States of America

Bio-Technology General Corporation

Forward Citations = 953

50 inventors:

Avigdor Levanon (26 out of 28 patents)

Amos B Oppenheim (20 out of 23 patents)

Marian Gorecki (19 out of 21 patents)

4. Jacob R Hartman (15 out of 32 patents)

5. Tikva Vogel (14 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bio-Technology General Corporation. Retrieved from https://idiyas.com/company/bio-technology-general

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…